|
Ranbaxy Laboratories Limited is an Indian company incorporated in 1961. It is India's largest pharmaceutical company. It exports its products to 125 countries with ground operations in 46 and manufacturing facilities in 7 countries. It is ranked among the top 10 generic companies worldwide. The CEO of the company is Malvinder Mohan Singh. Image File history File links Flag_of_India. ...
Malvinder Mohan Singh is the eldest son of the Parvinder the Chairman and managing director of Ranbaxy Laboratories. ...
Pharmacology (in Greek: pharmacon is drug, and logos is science) is the study of how chemical substances interfere with living systems. ...
A generic drug (pl. ...
Revenue is a U.S. business term for the amount of money that a company earns from its activities in a given period, mostly from sales of products and/or services to customers. ...
Image File history File links Green_Arrow_Up_(Darker). ...
Employment is a contract between two parties, one being the employer and the other being the employee. ...
A website (or Web site) is a collection of web pages, typically common to a particular domain name or subdomain on the World Wide Web on the Internet. ...
1961 (MCMLXI) was a common year starting on Sunday (the link is to a full 1961 calendar). ...
Pharmacology (in Greek: pharmacon is drug, and logos is science) is the study of how chemical substances interfere with living systems. ...
Malvinder Mohan Singh is the eldest son of the Parvinder the Chairman and managing director of Ranbaxy Laboratories. ...
Ranbaxy went public in 1973. 1973 (MCMLXXIII) was a common year starting on Monday. ...
In 1998, Ranbaxy entered the USA, the world's largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005. 1998 (MCMXCVIII) was a common year starting on Thursday of the Gregorian calendar, and was designated the International Year of the Ocean. ...
2005 (MMV) was a common year starting on Saturday of the Gregorian calendar. ...
For the twelve months ending on December 31, 2005, the Company's Global Sales were at US $1.178 billion with overseas markets accounting for 75% of global sales(USA: 28%, Europe: 17%, Brazil, Russia, India and China: 29%). World map showing the location of Europe. ...
Most of Ranbaxy's products are manufactured by license from foreign pharmaceutical developers, though a significant percentage of their products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired.
In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion.BBC
On June 23, 2006, Ranbaxy received from the U.S. Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug at 80 mg strength. Ranbaxy presently competes with the maker of brand-name Zocor, Merck & Co.; Teva Pharmaceutical Industries, which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories, also from India, whose authorized generic version (licensed by Merck) is exempt from exclusivity. Simvastatin (INN) (IPA: ) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. ...
A generic drug (pl. ...
It has been suggested that Rosetta Biosoftware be merged into this article or section. ...
Teva Pharmaceutical Industries Ltd. ...
Dr. Reddys Laboratories Ltd. ...
The emergence of at least one "Chinese Ranbaxy" over the next few years could catalyse consolidation in the generics segment in India and abroad, says Rajiv Shukla, vice-president of business development and marketing at Advinus Therapeutics. Speaking at IBC's 3rd annual international conference on pharma R&D partnering and innovation India, in Mumbai, Mr Shukla said that such a firm could be helped along by the Chinese government and provoke a pause for thought in and outside India. Ranbaxy is India's largest pharmaceutical company and a key player in the global generics market. Alluding to the formation of a similar business in China Mr Shukla told Scrip, "It will possibly be constructed by the Chinese government [Chinese firms facing consolidation could be combined] and would then go public." Indian firms are also expected to become active on both the buy and sell side of mergers and acquisitions. Mr Shukla expects international generics companies to make at least one $1 billion acquisition in India, with mid-market acquisitions remaining "lively". Mylan Laboratories recently acquired India's Matrix Laboratories for about $736 million in the largest ever acquisition in the Indian pharmaceutical industry. On the other hand, Indian generics companies, backed by increased confidence from their recent M&A experiences, are also expected to start making acquisition bids in the $1 billion range, and could acquire overseas R&D, Mr Shukla added. During the first quarter of this year, Indian pharma companies spent close to $1 billion in acquiring European assets, says a report by the Indian investment banking firm Mape Advisory.
External links
|
Feeds |
Contact